Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press33510.17650/1994-4098-2008-0-1-33-40PHARMACOTHERAPYГИНЕКОЛОГИЯ. ФАРМАКОТЕРАПИЯENDOCRINE TREATMENT OPTIONS FOR ADVANCED BREAST CANCER — THE ROLE OF FULVESTRANTРОЛЬ ФУЛВЕСТРАНТА В ЭНДОКРИННОЙ ТЕРАПИИ РАСПРОСТРАНЕННОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫRobertsonJ.F.R.RobertsonJ. F.R.
Russian Federation
ComeS.E.ComeS. E.
Russian Federation
JonesS.E.JonesS. E.
Russian Federation
BeexL.
Russian Federation
KaufmannM.
Russian Federation
MakrisA.
Russian Federation
NortierJ.W.R.NortierJ. W.R.
Russian Federation
PossingerK.
Russian Federation
RutqvistL.-E.
Russian Federation
Unit of Surgery, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UKBeth Israel Deaconess Medical Center, Boston, MA, USACharles A. Sammons Cancer Center, Dallas, TX, USAUniversity Medical Centre Nijmegen, Nijmegen, The NetherlandsGoethe University, Frankfurt, GermanyAcademic Oncology Unit, Mount Vernon Hospital, Middlesex, UKLeiden University Medical Center, Leiden, The NetherlandsHumboldt University Berlin, Berlin, GermanyKarolinska Institute, Stockholm, Sweden150220081334015092014150920142008https://ojrs.abvpress.ru/ojrs/article/view/335

For many years, tamoxifen has been the _gold standard_ amongst anti-oestrogen therapies for breast cancer. However, the selective aro- matase inhibitors (AIs), anastrozole, letrozole and exemestane, have demonstrated advantages over tamoxifen as first-line treatments for advanced disease. Anastrozole is also more effective as an adjuvant treatment in early, operable breast cancer and is being increasingly used in the adjuvant setting. Generally, the selective oestrogen receptor modulators (SERMs), such as toremifene, droloxifene, idoxifene, ralox- ifene, and arzoxifene, show minimal activity in tamoxifen-resistant disease and show no superiority over tamoxifen as first-line treatments. In addition to these agents, other treatment options for advanced disease include high-dose oestrogens and progestins. Response rates for high- dose oestrogens and tamoxifen are similar, but the use of oestrogens is limited by their toxicity profile. Consequently, there is a need for new endocrine treatment options for breast cancer, particularly for use in disease that is resistant to tamoxifen or AIs. Fulvestrant (_Faslodex_) is a new type of steroidal oestrogen receptor (ER) antagonist that downregulates cellular levels of the ER and progesterone receptor and has no agonist activity. This paper reviews the key efficacy and tolerability data for fulvestrant in postmenopausal women in the context of other endocrine therapies and explores the potential role of fulvestrant within the sequencing of endocrine therapies for advanced breast cancer.

РОЛЬ ФУЛВЕСТРАНТА В ЭНДОКРИННОЙ ТЕРАПИИ РАСПРОСТРАНЕННОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ

1. Bertelli G., Pronzato P., Amoroso D. et al. Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. Breast Cancer Res Treat 1988;12:307—10.Bertelli G., Pronzato P., Amoroso D. et al. Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. Breast Cancer Res Treat 1988;12:307—10.2. Powles T.J., Hickish T., Kanis J.A. et al. Effect of tamoxifen on bone mineral den- sity measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996;14:78—84.Powles T.J., Hickish T., Kanis J.A. et al. Effect of tamoxifen on bone mineral den- sity measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996;14:78—84.3. Fisher B., Constantino J.P., Redmond C.K. et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527—37.Fisher B., Constantino J.P., Redmond C.K. et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527—37.4. Nabholtz J.M., Buzdar A., Pollak M. et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter ran- domized trial. Arimidex Study Group. J Clin Oncol 2000;18:3758—67.Nabholtz J.M., Buzdar A., Pollak M. et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter ran- domized trial. Arimidex Study Group. J Clin Oncol 2000;18:3758—67.5. Bonneterre J., Thurlimann B., Robertson J.F. et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 post- menopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000;18:3748—57.Bonneterre J., Thurlimann B., Robertson J.F. et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 post- menopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000;18:3748—57.6. Mouridsen H., Gershanovich M., Sun Y. et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for post- menopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19:2596—606.Mouridsen H., Gershanovich M., Sun Y. et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for post- menopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19:2596—606.7. Mouridsen H., Gershanovich M., Sun Y. et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in post- menopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21:2101—9.Mouridsen H., Gershanovich M., Sun Y. et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in post- menopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21:2101—9.8. Dirix L., Piccart M.J., Lohrisch C. et al. Efficacy and tolerance to exemestane (E) versus tamoxifen (T) in 1st line hormone therapy (HT) of postmenopausal metastatic breast cancer (MBC) patients (pts): a European phase II trial with Pharmacia and Upjohn. Proc Am Soc Clin Oncol 2001;20:29A. [abstract 114].Dirix L., Piccart M.J., Lohrisch C. et al. Efficacy and tolerance to exemestane (E) versus tamoxifen (T) in 1st line hormone therapy (HT) of postmenopausal metastatic breast cancer (MBC) patients (pts): a European phase II trial with Pharmacia and Upjohn. Proc Am Soc Clin Oncol 2001;20:29A. [abstract 114].9. Stenbygaard L.E., Herrstedt J., Thomsen J.F. et al. Toremifene and tamoxifen in advanced breast cancer — a double-blind cross-over trial. Breast Cancer Res Treat 1993;25:57—63.Stenbygaard L.E., Herrstedt J., Thomsen J.F. et al. Toremifene and tamoxifen in advanced breast cancer — a double-blind cross-over trial. Breast Cancer Res Treat 1993;25:57—63.10. Vogel C.L., Shemano I., Schoenfelder J. et al. Multicenter Phase II efficacy trial of toremifene in tamoxifenrefractory patients with advanced breast cancer. J Clin Oncol 1993;11:345—50.Vogel C.L., Shemano I., Schoenfelder J. et al. Multicenter Phase II efficacy trial of toremifene in tamoxifenrefractory patients with advanced breast cancer. J Clin Oncol 1993;11:345—50.11. Pyrhonen S., Valavaara R., Vuorinen J., Hajba A. High dose toremifene in advanced breast cancer resistant to or relapsed during tamoxifen treatment. Breast Cancer Res Treat 1994;29:223—8.Pyrhonen S., Valavaara R., Vuorinen J., Hajba A. High dose toremifene in advanced breast cancer resistant to or relapsed during tamoxifen treatment. Breast Cancer Res Treat 1994;29:223—8.12. Pyrhonen S., Valavaara R., Modig H. et al. Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a random- ized double-blind, the «Nordic» Phase III study. Br J Cancer 1997;76:270—7.Pyrhonen S., Valavaara R., Modig H. et al. Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a random- ized double-blind, the «Nordic» Phase III study. Br J Cancer 1997;76:270—7.13. Pyrhonen S., Ellmen J., Vuorinen J. et al. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of anti-oestrogen therapy in postmenopausal women with breast cancer. Breast Cancer Res Treat 1999;56:133—43.Pyrhonen S., Ellmen J., Vuorinen J. et al. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of anti-oestrogen therapy in postmenopausal women with breast cancer. Breast Cancer Res Treat 1999;56:133—43.14. Holli K., Valavaara R., Blanco G. et al. Safety and efficacy results of a random- ized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group. J Clin Oncol 2000;18:3487—94.Holli K., Valavaara R., Blanco G. et al. Safety and efficacy results of a random- ized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group. J Clin Oncol 2000;18:3487—94.15. Haarstad H., Gundersen S., Wist E. et al. Droloxifene — a new anti-estrogen. A phase II study in advanced breast can- cer. Acta Oncol 1992;31:425—8.Haarstad H., Gundersen S., Wist E. et al. Droloxifene — a new anti-estrogen. A phase II study in advanced breast can- cer. Acta Oncol 1992;31:425—8.16. Buzdar A.U., Kau S., Hortobagyi G.N. et al. Phase I trial of droloxifene in patients with metastatic breast cancer. Cancer Chemother Pharmacol 1994;33:313—6.Buzdar A.U., Kau S., Hortobagyi G.N. et al. Phase I trial of droloxifene in patients with metastatic breast cancer. Cancer Chemother Pharmacol 1994;33:313—6.17. Buzdar A., Hayes D., El-Khoudary A. et al. Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer. Breast Cancer Res Treat 2002;73:161—75.Buzdar A., Hayes D., El-Khoudary A. et al. Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer. Breast Cancer Res Treat 2002;73:161—75.18. Coombes R.C., Haynes B.P., Dowsett M. et al. Idoxifene: a report of a phase I study in patients with metastatic breast cancer. Cancer Res 1995;55:1070—4.Coombes R.C., Haynes B.P., Dowsett M. et al. Idoxifene: a report of a phase I study in patients with metastatic breast cancer. Cancer Res 1995;55:1070—4.19. Johnston S.R. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies. Clin Cancer Res 2001;7(Suppl 12):4376S—4377S.Johnston S.R. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies. Clin Cancer Res 2001;7(Suppl 12):4376S—4377S.20. Buzdar A., O’Shaughnessy J.A., Booser D.J. et al. Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. J Clin Oncol 2003;21:1007—14.Buzdar A., O’Shaughnessy J.A., Booser D.J. et al. Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. J Clin Oncol 2003;21:1007—14.21. Buzdar A.U., Marcus C., Holmes F. et al. Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology 1988;45:344—5.Buzdar A.U., Marcus C., Holmes F. et al. Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology 1988;45:344—5.22. Cauley J.A., Norton L., Lippman M.E. et al. Continued breast cancer risk reduc- tion in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of ralox- ifene evaluation. Breast Cancer Res Treat 2001;65:125—34.Cauley J.A., Norton L., Lippman M.E. et al. Continued breast cancer risk reduc- tion in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of ralox- ifene evaluation. Breast Cancer Res Treat 2001;65:125—34.23. Dickler M.N., Norton L. The MORE trial: multiple outcomes for raloxifene evaluation — breast cancer as a secondary end point: implications for prevention. Ann N Y Acad Sci 2001;949:134—42.Dickler M.N., Norton L. The MORE trial: multiple outcomes for raloxifene evaluation — breast cancer as a secondary end point: implications for prevention. Ann N Y Acad Sci 2001;949:134—42.24. Jubelirer S.J., Crowell Jr. E.B. The STAR (study of tamoxifen and ralox- ifene) trial in West Virginia. W V Med J 2000;96:602—4.Jubelirer S.J., Crowell Jr. E.B. The STAR (study of tamoxifen and ralox- ifene) trial in West Virginia. W V Med J 2000;96:602—4.25. Ingle J.N. Estrogen as therapy for breast cancer. Breast Cancer Res 2002;4:133—6.Ingle J.N. Estrogen as therapy for breast cancer. Breast Cancer Res 2002;4:133—6.26. Peethambaram P.P., Ingle J.N., Suman V.J. et al. Randomized trial of diethylstilbestrol versus tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. Breast Cancer Res Treat 1999;54:117—22.Peethambaram P.P., Ingle J.N., Suman V.J. et al. Randomized trial of diethylstilbestrol versus tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. Breast Cancer Res Treat 1999;54:117—22.27. Lшnning P.E., Taylor P.D., Anker G. et al. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 2001;67:111—6.Lшnning P.E., Taylor P.D., Anker G. et al. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 2001;67:111—6.28. Hu X.F., Veroni M., De Luise M. et al. Circumvention of tamoxifen resist- ance by the pure anti-estrogen ICI 182,780. Int J Cancer 1993;55:873—6.Hu X.F., Veroni M., De Luise M. et al. Circumvention of tamoxifen resist- ance by the pure anti-estrogen ICI 182,780. Int J Cancer 1993;55:873—6.29. DeFriend D.J., Howell A., Nicholson R.I. et al. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 1994;54:408—14.DeFriend D.J., Howell A., Nicholson R.I. et al. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 1994;54:408—14.30. Osborne C.K., Jarman M., McCague R. et al. The importance of tamoxifen metabolism in tamoxifen- stimulated breast tumor growth. Cancer Chemother Pharmacol 1994;34:89—95.Osborne C.K., Jarman M., McCague R. et al. The importance of tamoxifen metabolism in tamoxifen- stimulated breast tumor growth. Cancer Chemother Pharmacol 1994;34:89—95.31. Howell A. Preliminary experience with pure antiestrogens. Clin Cancer Res 2001;7(Suppl 12):4369s—75s.Howell A. Preliminary experience with pure antiestrogens. Clin Cancer Res 2001;7(Suppl 12):4369s—75s.32. Nicholson R.I., Gee J.M., Manning D.L. et al. Responses to pure anti-oestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and -resist- ant experimental and clinical breast can- cer. Ann N Y Acad Sci 1995;761:148—63.Nicholson R.I., Gee J.M., Manning D.L. et al. Responses to pure anti-oestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and -resist- ant experimental and clinical breast can- cer. Ann N Y Acad Sci 1995;761:148—63.33. Pink J.J., Jordan V.C. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res 1996;56:2321—30.Pink J.J., Jordan V.C. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res 1996;56:2321—30.34. Hutcheson I.R., Knowlden J.M., Barrow D. et al. The novel ER down-reg- ulator, Faslodex, modulates EGFR/MAPK activity in tamoxifen- resistant MCF-7 breast cancer cells. Clin Cancer Res 2001;7:557. [abstract].Hutcheson I.R., Knowlden J.M., Barrow D. et al. The novel ER down-reg- ulator, Faslodex, modulates EGFR/MAPK activity in tamoxifen- resistant MCF-7 breast cancer cells. Clin Cancer Res 2001;7:557. [abstract].35. Hutcheson I.R., Knowlden J.M., Gee J.M.W. et al. Oestrogen receptor- mediated modulation of the EGFR/MAPK signalling pathway in tamoxifen-resistant MCF-7 breast cancer cells. Breast Cancer Res Treat 2003;81:81—93.Hutcheson I.R., Knowlden J.M., Gee J.M.W. et al. Oestrogen receptor- mediated modulation of the EGFR/MAPK signalling pathway in tamoxifen-resistant MCF-7 breast cancer cells. Breast Cancer Res Treat 2003;81:81—93.36. Robertson J.F., Nicholson R.I., Bundred N.J. et al. Comparison of the short-term biological effects of 7a-[9- (4,4,5,5,5-pentafluoropentylsulfinyl)- nonyl]estra-1,3,5,(10)-triene-3,17b-diol (Faslodex) versus tamoxifen in post- menopausal women with primary breast cancer. Cancer Res 2001;61:6739—46.Robertson J.F., Nicholson R.I., Bundred N.J. et al. Comparison of the short-term biological effects of 7a-[9- (4,4,5,5,5-pentafluoropentylsulfinyl)- nonyl]estra-1,3,5,(10)-triene-3,17b-diol (Faslodex) versus tamoxifen in post- menopausal women with primary breast cancer. Cancer Res 2001;61:6739—46.37. Bundred N.J., Anderson E., Nicholson R.I. et al. Fulvestrant, an estrogen receptor downregulator, reduces cell turnover index more effectively than tamoxifen. Anticancer Res 2002;22:2317—9.Bundred N.J., Anderson E., Nicholson R.I. et al. Fulvestrant, an estrogen receptor downregulator, reduces cell turnover index more effectively than tamoxifen. Anticancer Res 2002;22:2317—9.38. Osborne C.K., Pippen J., Jones S.E. et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in post- menopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American Trial. J Clin Oncol 2002;20:3386—95.Osborne C.K., Pippen J., Jones S.E. et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in post- menopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American Trial. J Clin Oncol 2002;20:3386—95.39. Howell A., Robertson J.F., Quaresma Albano J. et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmen-opausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20:3396—403.Howell A., Robertson J.F., Quaresma Albano J. et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmen-opausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20:3396—403.40. Robertson J.F., Osborne C.K., Howell A. et al. Fulvestrant versus anas- trozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003;98:229—38.Robertson J.F., Osborne C.K., Howell A. et al. Fulvestrant versus anas- trozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003;98:229—38.41. Mauriac L., Pippen J.E., Quaresma Albano J. et al. Fulvestrant (FaslodexTM) versus anastrozole for the treatment of advanced breast cancer in a subgroup of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. Eur J Cancer 2003;39:1228—33.Mauriac L., Pippen J.E., Quaresma Albano J. et al. Fulvestrant (FaslodexTM) versus anastrozole for the treatment of advanced breast cancer in a subgroup of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. Eur J Cancer 2003;39:1228—33.42. Vergote I., Robertson J.F.R., Kleeberg U. et al. Postmenopausal women who progress on fulvestrant («Faslodex») remain sensitive to further endocrine therapy. Breast Cancer Res Treat 2003;79:207—11.Vergote I., Robertson J.F.R., Kleeberg U. et al. Postmenopausal women who progress on fulvestrant («Faslodex») remain sensitive to further endocrine therapy. Breast Cancer Res Treat 2003;79:207—11.43. Robertson J.F.R., Howell A., Abram P. et al. Fulvestrant versus tamox- ifen for the first-line treatment of advanced breast cancer (ABC) in post- menopausal women. Ann Oncol 2002;13(Suppl 5):46. [abstract 1640].Robertson J.F.R., Howell A., Abram P. et al. Fulvestrant versus tamox- ifen for the first-line treatment of advanced breast cancer (ABC) in post- menopausal women. Ann Oncol 2002;13(Suppl 5):46. [abstract 1640].44. Howell A. Postmenopausal women with advanced breast cancer who progress on Fulvestrant or tamoxifen retain sensi- tivity to further endocrine therapies. Breast Cancer Res Treat 2002;76(Suppl 1):S72. [abstract 251].Howell A. Postmenopausal women with advanced breast cancer who progress on Fulvestrant or tamoxifen retain sensi- tivity to further endocrine therapies. Breast Cancer Res Treat 2002;76(Suppl 1):S72. [abstract 251].45. Beyea S., Nicoll L.H. Back to basics. Administering i.m. injections the right way. Am J Nurs 1996;96:34—5.Beyea S., Nicoll L.H. Back to basics. Administering i.m. injections the right way. Am J Nurs 1996;96:34—5.46. Robertson J.F.R., Harrison M.P. Equivalent single-dose pharmacokinetics of two different dosing methods of pro- longed-release fulvestrant («Faslodex») in postmenopausal women with advanced breast cancer. Cancer Chemother Pharmacol 2003;52:346—8.Robertson J.F.R., Harrison M.P. Equivalent single-dose pharmacokinetics of two different dosing methods of pro- longed-release fulvestrant («Faslodex») in postmenopausal women with advanced breast cancer. Cancer Chemother Pharmacol 2003;52:346—8.47. The ATAC Trialists’ Group. Arimidex, tamoxifen alone or in combi- nation. Anastrozole alone or in combina- tion with tamoxifen versus tamoxifen alone for adjuvant treatment of post- menopausal women with early breast cancer: first results of the ATAC ran- domised trial. Lancet 2002;359:2131—9.The ATAC Trialists’ Group. Arimidex, tamoxifen alone or in combi- nation. Anastrozole alone or in combina- tion with tamoxifen versus tamoxifen alone for adjuvant treatment of post- menopausal women with early breast cancer: first results of the ATAC ran- domised trial. Lancet 2002;359:2131—9.48. Perey L., Thurlimann B., Hawle H. et al. Fulvestrant («Faslodex») as hor- monal treatment in postmenopausal patients with advanced breast cancer progressing after treatment with tamox- ifen and aromatase inhibitors. Breast Cancer Res Treat 2002;76(Suppl 1):S72. [abstract 249].Perey L., Thurlimann B., Hawle H. et al. Fulvestrant («Faslodex») as hor- monal treatment in postmenopausal patients with advanced breast cancer progressing after treatment with tamox- ifen and aromatase inhibitors. Breast Cancer Res Treat 2002;76(Suppl 1):S72. [abstract 249].49. Lшnning P.E., Bajetta E., Murray R. et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a Phase II trial. J Clin Oncol 2000;18:2234—44.Lшnning P.E., Bajetta E., Murray R. et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a Phase II trial. J Clin Oncol 2000;18:2234—44.50. Kaufmann M., Bajetta E., Dirix L.Y. et al. Exemestane is superior to megestrol acetate after tamoxifen failure in post- menopausal women with advanced breast cancer: results if a Phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000;18:1399—411.Kaufmann M., Bajetta E., Dirix L.Y. et al. Exemestane is superior to megestrol acetate after tamoxifen failure in post- menopausal women with advanced breast cancer: results if a Phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000;18:1399—411.51. Bertelli G., Garrone O., Merlano M. Sequential use of aromatase inactivators and inhibitors in advanced breast cancer. Proc Am Soc Clin Oncol 2002;21:60A. [abstract 238].Bertelli G., Garrone O., Merlano M. Sequential use of aromatase inactivators and inhibitors in advanced breast cancer. Proc Am Soc Clin Oncol 2002;21:60A. [abstract 238].52. DeFriend D.J., Anderson E., Bell J. et al. Effects of 4-hydroxytamoxifen and a novel pure anti-oestrogen (ICI 182870) on the clonogeneic growth of human breast cancer cells in vitro. Br J Cancer 1994;70:204—11.DeFriend D.J., Anderson E., Bell J. et al. Effects of 4-hydroxytamoxifen and a novel pure anti-oestrogen (ICI 182870) on the clonogeneic growth of human breast cancer cells in vitro. Br J Cancer 1994;70:204—11.53. Nicholson R.I., Hutcheson I.R., Harper M.E. et al. Modulation of epider- mal growth factor receptor in endocrine- resistant, oestrogen receptor-positive breast cancer. Endocr Relat Cancer 2001;8:175—82.Nicholson R.I., Hutcheson I.R., Harper M.E. et al. Modulation of epider- mal growth factor receptor in endocrine- resistant, oestrogen receptor-positive breast cancer. Endocr Relat Cancer 2001;8:175—82.54. Wakeling A., Nicholson R.I., Gee J.M. Prospects for combining hormonal and non-hormonal growth factor inhibition. Clin Cancer Res 2001;1(Suppl 12):4350S—55S.Wakeling A., Nicholson R.I., Gee J.M. Prospects for combining hormonal and non-hormonal growth factor inhibition. Clin Cancer Res 2001;1(Suppl 12):4350S—55S.